Josefine Bostner

Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer

Josefine Bostner, Marie Ahnström Waltersson, Tommy� Fornander et al. · Oncogene · 2007 · 195 citations

Postmenopausal Breast Cancer, Breast Oncology, Tamoxifen Resistance +9

The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials

Elin Karlsson, Gizeh Pérez‐Tenorio, Risul Amin et al. · Breast Cancer Research · 2013 · 106 citations · Full text

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit

Josefine Bostner, Elin Karlsson, Muneeswaran Jayachandra Pandiyan et al. · Breast Cancer Research and Treatment · 2012 · 97 citations · Full text

Breast Oncology, Estrogen Receptor, Gynecology +25

High‐resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1

Elin Karlsson, Marie Ahnström Waltersson, Josefine Bostner et al. · Genes Chromosomes and Cancer · 2011 · 80 citations · Full text

Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer

Josefine Bostner, Lambert Skoog, Tommy� Fornander et al. · Clinical Cancer Research · 2010 · 58 citations · Full text